Jean Jacques Bienaime, a member of Immunome Inc.'s board, acquired 2,000 shares of the company’s common stock in two transactions in March 2026, for a total outlay of $43,670.
On March 10, 2026, Bienaime purchased 1,000 shares at $22.12 apiece, a transaction valued at $22,120. The following day, March 11, 2026, he added another 1,000 shares at $21.55 per share, costing $21,550. After these purchases, Bienaime directly owns 38,415 shares of Immunome.
The insider purchases arrive as Immunome’s shares have climbed 132% over the past year, though the stock is described as remaining volatile. InvestingPro analysis cited in company commentary indicates the shares currently appear undervalued relative to its Fair Value assessment. The company carries a market capitalization of $2.42 billion and, according to the same analysis, holds more cash than debt on its balance sheet.
Alongside the insider activity, Immunome has priced a public offering of 18.625 million shares at $21.50 per share, expected to generate approximately $400 million in gross proceeds. The company has stated that proceeds from the offering are intended to support the potential commercial launch of its lead asset, varegacestat, and to advance further development across its pipeline.
In a related financing move, Immunome secured a $400 million equity financing that company materials indicate should extend its financial runway into 2028. Following these capital raises, several sell-side firms reiterated or initiated coverage with favorable ratings: Guggenheim maintained a Buy rating and a $35 price target, raising that target from $25 to $35 after positive Phase 3 trial results for varegacestat in desmoid tumors. The trial data reportedly showed a progression-free survival hazard ratio of 0.16 versus the FDA-approved comparator. H.C. Wainwright also initiated coverage with a Buy rating and set a $40 price target, highlighting the company’s oncology portfolio.
These developments - insider purchases, a large public offering, a separate equity financing and favorable analyst actions - mark a period of coordinated financial and clinical activity for Immunome as it prepares for potential commercialization steps and continued pipeline advancement.